Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 13/20 | 0.56 |
| ▸ | TDO2 | P48775 | 13/20 | 0.56 |
| ▸ | METAP2 | P50579 | 1/20 | 0.47 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17739262 | 0.84 | TDO2 (0.52) | IDO1TDO2METAP2BRAFEIF2AK3 | |
| SCHEMBL17739099 | 0.73 | METAP2 (0.50) | IDO1TDO2METAP2 | |
| SCHEMBL19249211 | 0.72 | TDO2 (0.55) | IDO1TDO2 | |
| SCHEMBL17738828 | 0.70 | METAP2 (0.50) | IDO1TDO2METAP2 | |
| SCHEMBL1060004 | 0.70 | CYP2C19 (0.54) | IDO1TDO2 | |
| SCHEMBL14487466 | 0.69 | METAP2 (0.56) | IDO1TDO2METAP2 | |
| SCHEMBL28673206 | 0.68 | TDO2 (0.81) | IDO1TDO2 | |
| SCHEMBL2905439 | 0.68 | EGFR (0.41) | IDO1TDO2 | |
| SCHEMBL470105 | 0.66 | METAP2 (0.53) | IDO1TDO2METAP2BRAFEIF2AK3 | |
| SCHEMBL2003535 | 0.66 | METAP2 (0.53) | IDO1TDO2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11130738-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2021-09-28 | — | — | US | disclosed |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD. (GB) | 2020-06-04 | — | — | US | disclosed |
| US-10590086-B2 | Pharmaceutical compound | IOMET PHARMA LTD. (GB) | 2020-03-17 | — | — | US | disclosed |
| WO-2016071293-A2 | PHARMACEUTICAL COMPOUND | IOMET PHARMA LTD (GB) | 2016-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11130738-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | IDO1 1/4885TDO2 2/4885METAP2 840/4885 |
| US-20200172492-A1 | PHARMACEUTICAL COMPOUND | IDO1, TDO2, IDO2 | IDO1 1/4885TDO2 2/4885METAP2 840/4885 |
| US-10590086-B2 | Pharmaceutical compound | IDO1, TDO2, IDO2 | IDO1 1/4885TDO2 2/4885METAP2 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.